# Tandem Diabetes Care account plan

> Tandem Diabetes Care makes automated insulin delivery pumps (t:slim X2, Tandem Mobi); FY2025 sales $1,014.7 million, about 2,500 employees.

## At a glance

Tandem Diabetes Care (Nasdaq: TNDM) is a San Diego company that designs and sells automated insulin delivery (AID) systems: the t:slim X2 and Tandem Mobi pumps running Control-IQ+, plus single-use cartridges and infusion sets. It serves nearly 500,000 people with diabetes in more than 25 countries, selling directly in the U.S. and Canada and mostly through distributors elsewhere. FY2025 sales were $1,014.7 million (FY2024: $940.2 million), with a gross margin of 54% and a net loss of $204.7 million. It had about 2,500 regular full-time employees at end-2025, with headquarters, R&D and pump assembly in San Diego.

## Business units

- **United States - Pumps** (about 35% of FY2025 sales ($353.9 million)): t:slim X2 and Tandem Mobi pumps sold mainly through the DME (medical) benefit via distributors, and increasingly through the pharmacy channel. More than 86,000 U.S. pumps shipped in 2025. Under pay-as-you-go there is no upfront pump reimbursement, so U.S. pump sales fell slightly to $83.4 million in Q3 2026.
- **United States - Supplies and other** (about 35% of FY2025 sales ($353.1 million)): Cartridges, infusion sets and other recurring products for an installed base of nearly 330,000 U.S. customers. Pharmacy supplies are reimbursed at a premium to the DME model, and U.S. supplies rose to $107.7 million in Q3 2026 from $90.8 million.
- **International - Pumps** (about 11% of FY2025 sales ($110.3 million)): Pumps sold in more than 25 countries, historically through distributors, with direct operations in the UK, Switzerland and Austria and France launching. More than 40,000 pumps shipped in 2025; Tandem Mobi is available in 12 international countries.
- **International - Supplies and other** (about 19% of FY2025 sales ($197.5 million)): Recurring supplies for the international installed base, including rental models in some countries. Direct sales were 18% of international sales in Q3 2026 vs 3% a year earlier.

## Strategic priorities

- **Reshaping the business model: pay-as-you-go pharmacy**: Since Q1 2026 U.S. pharmacy contracts use pay-as-you-go, with no upfront pump reimbursement and a price premium on supplies. Pharmacy reached 15% of U.S. sales in Q3 2026 with about 50% formulary coverage, and management expects "almost all pharmacy as opposed to DME" by end of 2028.
- **Going direct internationally**: Direct sales, training and support started in 2026 in the UK, Austria and Switzerland, with France launching; Tandem aims to serve "approximately half of our installed base by the end of next year".
- **Mobi tubeless launch**: A 510(k) for Mobi tubeless, "the world's first and only tubeless AID system" with up to seven days of wear, was submitted in Q2 2026; clearance is expected in Q4 and full commercial availability in the first half of 2027.
- **Fully closed loop system**: With the University of Virginia, Tandem is developing a system that needs no meal announcements; a pivotal study of more than 300 people starts in Q4 2026, with the product expected on the market in 2028.
- **Modernizing the commercial organization**: A new CRM system was deployed in 2026 "to improve sales force efficiency and effectiveness" and support the pharmacy transition and international direct launches.
- **Type 2 expansion**: Control-IQ+ was cleared in March 2025 for type 2 diabetes ages 18+, adding about 2.5 million U.S. people with type 2 diabetes who require intensive insulin therapy to the addressable market.

## Latest results

In Q3 2026 (quarter to 30 September 2026) sales rose 14% to $283.7 million: U.S. $191.0 million (+9%) and international $92.6 million (+26%). Gross margin rose to 57% from 54% on pharmacy and direct pricing, the operating loss narrowed to $2.4 million from $22.9 million, and adjusted EBITDA was $18.0 million, or 6% of sales. About 33,000 pumps shipped worldwide. Tandem reaffirmed 2026 guidance of about $1.065 billion to $1.085 billion of sales, a 56% to 57% gross margin and a 5% to 6% adjusted EBITDA margin; for 2027 the CFO said a "mid to high single digit increase year over year is probably a really fair starting point".

## Investments and deals

- **AMF Medical (Sigi Patch Pump)**: An amended agreement in January 2025 replaced contingent earnouts with CHF 68.0 million ($75.2 million), booked as acquired IPR&D; Sigi technology underpins the next-generation Mobi patch pump.
- **CeQur stake**: An additional CHF 64.0 million ($81.4 million) investment in CeQur SA on 22 May 2026, keeping ownership below 50%; carrying value $125.5 million.
- **Roche cross-licence**: The May 2025 settlement and cross-licence costs $36.0 million over four years for 10-year cross-licences.
- **Convertible notes**: $300.0 million of 0.00% convertible notes due 2032 issued in February 2026, alongside $316.3 million of 1.50% notes due 2029; cash and short-term investments were $443.1 million at 30 September 2026.

## Challenges and risks

- **Infusion set supply constraint**: A key infusion set supplier's shortages hit supply sales, with constraints expected to persist through early 2027; all currently marketed infusion sets come from Unomedical, a ConvaTec subsidiary.
- **Slower pharmacy adoption**: Management said "the pace of transition is more gradual than we initially anticipated", and pay-as-you-go initially reduces sales and gross profit on pump shipments.
- **Continued losses**: The FY2025 net loss was $204.7 million and the accumulated deficit $1.3 billion; profitability depends on sales growth, cost reduction and launches.
- **Competition and CGM partner dependence**: Tandem competes with Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed) and Sequel, and relies on CGM integration agreements with Dexcom and Abbott.
- **CEO transition**: John Sheridan retires at the end of 2026; Jeanette Bankas joined as president and CEO on November 16.

## What leadership says

> "Tandem's third-quarter performance demonstrates that our strategy is delivering results" — John Sheridan, President and CEO, Q3 2026 earnings press release, 5 November 2026

> "this is going to be a game changer for the business." — John Sheridan, President and CEO, On the fully closed loop system, Q3 2026 earnings call, 5 November 2026

> "reshaping our business model, modernizing our commercial organization, and delivering new technology" — John Sheridan, President and CEO, The three 2026 priorities, Q2 2026 earnings call, 6 August 2026

> "mid to high single digit increase year over year is probably a really fair starting point" — Leigh Vosseller, EVP, CFO and Treasurer, On 2027 expectations, Q3 2026 earnings call, 5 November 2026


## Where a supplier can help

- **Pharmacy channel operations**: The pay-as-you-go pharmacy priority, and adoption that is more gradual than expected, point to needs in prescription workflows, payer and PBM contracting support, and patient onboarding.
- **Direct operations in Europe**: Going direct in the UK, Switzerland, Austria and France means Tandem now handles reimbursement, tenders and fulfilment itself, creating demand for logistics, customer support and local market-access partners.
- **Infusion set supply resilience**: The infusion set supply constraint and single-supplier dependence make second-source manufacturing, supply chain planning and contract manufacturing relevant, as does the planned launch of its own SteadySet.
- **Sales force tooling**: The commercial modernization priority and new CRM system open room for sales enablement, CRM integration and analytics vendors supporting U.S. and international sales teams.
- **Clinical and launch support**: The Mobi tubeless launch and the fully closed loop pivotal study of more than 300 people call for clinical research, regulatory and manufacturing scale-up services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1438133/000143813326000010/tndm-20251231.htm)

Annual report · 2026-02-19

- Tandem Diabetes Care (Nasdaq: TNDM, San Diego) designs and sells automated insulin delivery (AID) systems: the t:slim X2 and Tandem Mobi pumps, both running Control-IQ+ technology, plus single-use cartridges and infusion sets; it serves nearly 500,000 people in more than 25 countries.
- FY2025 sales were $1,014.7 million (FY2024: $940.2 million): United States $706.9 million, International $307.8 million; more than 126,000 pumps shipped worldwide.
- Gross margin rose to 54% from 52%, but the net loss widened to $204.7 million, driven by $75.2 million of acquired IPR&D (revised AMF Medical / Sigi Patch Pump agreement) and $20.0 million of Roche settlement expense.
- Strategy: "redefine global leadership in insulin delivery solutions through commercial excellence, patient-first reimbursement choices, and a differentiated device portfolio"; Control-IQ+ was cleared in March 2025 for type 2 diabetes ages 18+, widening the addressable market.
- U.S. reimbursement shift: from 2026 pharmacy-benefit contracts move to a "pay as you go" model with no upfront pump reimbursement and a price premium on supplies; pharmacy was 4% of U.S. sales in 2025.
- International go-direct: direct sales, training and support began in 2026 in the United Kingdom, Austria and Switzerland, with more markets to follow during 2026.
- Pipeline: a tubeless, extended-wear infusion site option for Mobi, a next-generation Mobi patch pump using Sigi technology, extended-wear infusion sets, dual glucose-ketone sensor integration and fully closed loop algorithms.
- Risks: dependence on Dexcom and Abbott CGM integration agreements, a single third-party infusion set supplier (Unomedical, ConvaTec Group), competition from Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed) and Sequel, and reimbursement changes; accumulated deficit of $1.3 billion.
- About 2,500 regular full-time employees at end-2025; cash and short-term investments of $292.7 million; $316.3 million of 1.50% convertible notes due 2029.

### [Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1438133/000143813326000144/tndm-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 (quarter to 30 September 2026) sales were $283.7 million vs $249.3 million: United States $191.0 million (Q3 2025: $175.6 million), International $92.6 million (Q3 2025: $73.6 million).
- Gross margin rose to 57% from 54%, driven by favourable pricing from U.S. pharmacy sales and direct international sales; operating loss narrowed to $2.4 million from $22.9 million; net loss $7.1 million.
- Approximately 33,000 pumps shipped worldwide in the quarter: nearly 23,000 in the U.S. and nearly 11,000 internationally.
- Pharmacy channel (pay-as-you-go since Q1 2026) was 15% of U.S. sales in Q3 2026 vs 5% a year earlier; U.S. pump sales fell slightly to $83.4 million while supplies rose to $107.7 million.
- Direct sales were 18% of international sales in Q3 2026 vs 3%; Switzerland's rental customers moved to direct servicing.
- Pipeline: 510(k) submitted in Q2 2026 for Mobi tubeless capability.
- Supply risk: a key infusion set supplier's shortages hit supply sales, with constraints expected to persist through early 2027.
- Financing: $300.0 million of 0.00% convertible notes due 2032 issued in February 2026; additional CHF 64.0 million ($81.4 million) investment in CeQur; cash and short-term investments of $443.1 million at 30 September 2026.

### [Tandem Diabetes Care Announces Third Quarter 2026 Financial Results (press release, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1438133/000143813326000143/ex991-q3earningsrelease2026.htm)

Interim report · 2026-11-05

- Q3 2026 sales of $283.7 million worldwide, up 14% (also 14% in constant currency), including $191.0 million in the U.S. (+9%) and $92.6 million internationally (+26%, +27% in constant currency).
- Gross margin 57%, up 270 basis points; operating margin improved 830 basis points; operating loss $2.4 million and net loss $7.1 million.
- Adjusted EBITDA $18.0 million, or 6% of sales, vs $2.8 million (1%) in Q3 2025.
- Pharmacy channel reached 15% of U.S. sales under the pay-as-you-go model; formulary coverage about 50% of U.S. lives.
- Tandem Mobi available in 12 international countries; t:slim X2 compatibility with Abbott FreeStyle Libre 3 Plus extended to 11 international markets.
- 2026 guidance reaffirmed: sales of about $1.065 billion to $1.085 billion (U.S. $730-745 million, International $335-340 million), gross margin 56% to 57%, adjusted EBITDA margin 5% to 6%.
- Cash, cash equivalents and short-term investments of $443.1 million at 30 September 2026; convertible notes of $603.4 million (net, long-term).

### [Q3 2026 earnings call transcript](https://www.earningswhispers.com/transcript/TNDM/Q32026)

Executive talk · John Sheridan, President and Chief Executive Officer · 2026-11-05

- Final earnings call of CEO John Sheridan, who retires at the end of 2026; Chair Becky Robertson introduced Jeanette Bankas as the next president and CEO, joining on November 16.
- Q3 2026: worldwide revenue up 14% to $284 million, pump shipments up 12% to about 33,000; U.S. sales $191 million (+9%), international a record $93 million (+26%).
- Pharmacy pay-as-you-go reached 15% of U.S. sales and about 50% formulary coverage; supply pricing "averaging closer to 400" dollars a month vs the $350 baseline, but adoption is "more gradual than we initially anticipated".
- CFO Leigh Vosseller reset 2027 expectations: "mid to high single digit increase year over year is probably a really fair starting point".
- Mobi tubeless, "the world's first and only tubeless AID system" with up to seven days of wear, is in late-stage FDA review; clearance expected in Q4 and full commercial availability in the first half of 2027.
- International direct operations in the UK, Switzerland and Austria, France launching; about half of the installed base to be served directly by end-2027.
- Fully closed loop system based on UVA's algorithm: pivotal study of more than 300 people to start in Q4 2026, product on the market expected in 2028.
- Gross margin 57%, adjusted EBITDA 6% of sales (fifth consecutive positive quarter), cash and investments $443 million.

### [Q2 2026 earnings call transcript](https://allmind.ai/earnings/event/2936889)

Executive talk · John Sheridan, President and Chief Executive Officer · 2026-08-06

- Q2 2026 call (6 August 2026): CEO John Sheridan set out three priorities for the year: reshaping the business model, modernizing the commercial organization and delivering new technology.
- Results per CFO Leigh Vosseller: about 33,000 pumps shipped, worldwide sales $255 million (+6%), U.S. $179 million (+5%), international $75 million (+7%); gross margin 57%, up 5 points; adjusted EBITDA 3% of sales.
- Pay-as-you-go pharmacy launched in March: about 10% of U.S. sales, approximately 45% formulary coverage, contracts with the top three PBMs; initial pump headwind of about $8 million in the quarter.
- Mobi tubeless 510(k) filed in Q2, "the world's first with extended wear technology"; Sheridan called its launch "an inflection point in our revenue curve".
- FDA approved an IDE for a fully closed loop system based on UVA's AIDANET algorithm; pivotal study planned later in 2026.
- Commercial modernization: new CRM system deployed; direct operations in the UK, Switzerland and Austria, France planned for Q4; Mobi to more than 10 international countries by year-end.
- Infusion set supply shortages from the key supplier peaked in Q2; AutoSoft Plus launched in Canada; additional strategic investment in CeQur.
- Guidance reaffirmed: U.S. sales $730-745 million, international $335-340 million, gross margin 56% to 57%, adjusted EBITDA margin 5% to 6%.

## Questions about Tandem Diabetes Care

### What does Tandem Diabetes Care do?

Tandem designs and sells automated insulin delivery systems, the t:slim X2 and Tandem Mobi pumps running Control-IQ+, plus the cartridges and infusion sets they use. It serves nearly 500,000 people with diabetes in more than 25 countries.

### What is Tandem Diabetes Care's revenue?

FY2025 sales were $1,014.7 million. Q3 2026 sales were $283.7 million (+14%), and 2026 guidance is about $1.065 billion to $1.085 billion.

### How many employees does Tandem Diabetes Care have?

About 2,500 regular full-time employees at 31 December 2025, mainly in the United States, Canada and Europe.

### Who leads Tandem Diabetes Care?

Jeanette Bankas joined as president and CEO on November 16, succeeding John Sheridan, who retires at the end of 2026. Leigh Vosseller is CFO and Becky Robertson chairs the Board.

### What is Tandem Diabetes Care's strategy?

Tandem aims to grow through U.S. pay-as-you-go pharmacy reimbursement, direct international operations, and new technology such as Mobi tubeless and a fully closed loop system.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
